Belite Bio Completes Rolling NDA Submission for Tinlarebant in Rare Retinal Disease

Belite Bio Completes Rolling NDA Submission for Tinlarebant in Rare Retinal Disease

On June 12, 2026, Belite Bio completed the rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant (LBS-008), an investigational once-daily oral therapy for Stargardt disease type 1 (STGD1). STGD1 is a rare, inherited retinal disease caused by mutations in the ABCA4 gene, leading to progressive and irreversible central vision loss. The disease affects approximately 53,000 people in the U.S., and there are currently no FDA-approved treatment options.

The rolling NDA submission, which began in April 2026, was conducted under the FDA's Breakthrough Therapy Designation (BTD) pathway.¹ The completed application has now entered the FDA's standard 60-day filing review period. If accepted, the FDA will assign a Prescription Drug User Fee Act (PDUFA) target action date (expected in early August 2026).

Tinlarebant is designed to reduce the accumulation of vitamin A-based toxins (bisretinoids) in the retina by binding to retinol-binding protein 4 (RBP4), the transport protein that carries retinol from the liver to the eye. The NDA is supported by clinical data, including results from the Phase 3 DRAGON trial, which met its primary endpoint by demonstrating a statistically significant reduction in the growth rate of atrophic retinal lesions compared to placebo in patients with STGD1.

Verbatim Quotes

• "today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant." — Markets Insider
• "The completed application will undergo the 60-day review period with the FDA, and if accepted, a Prescription Drug User Fee Act (PDUFA) target action date will be assigned." — Markets Insider